BRAF and central nervous system cancer: BRAFV600E mutation (Class I) and BRAF-fusions (Class II) have been detected in 90% of pediatric low-grade gliomas, whereas mutations in histone H3-encoding genes have been identified in 50% of pediatric high-grade gliomas [55].